| A Proposed Tetra-modal Treatment Protocol for Muscle Invasive Urothelial Carcinoma of the Urinary Bladder (NCT05503563) | Assiut University | 2022-07-15 |
| Loop Resection or Cold-cup Biopsy? A Study Comparing the Accuracy of Muscle Samples During Bladder Tumor Surgery (NCT06796413) | University of Stellenbosch | 2022-07-14 |
| Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer (NCT05312671) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2022-06-27 |
| Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC (NCT04630730) | Swiss Cancer Institute | 2022-06-24 |
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05375903) | UroGen Pharma Ltd. | 2022-06-01 |
| Effect of Fresh Gas Flow on Emergence Time (NCT05376631) | Asan Medical Center | 2022-05-20 |
| Augmented Bladder Tumor Detection Using Real Time Based Artificial Intelligence (NCT05415631) | Centre Hospitalier Universitaire, Amiens | 2022-05-13 |
| cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (NCT05366881) | Adela, Inc | 2022-05-03 |
| Validation Study of Uromonitor in High Risk Microhematuria Patients (NCT05344937) | Clinica Universidad de Navarra, Universidad de Navarra | 2022-05-02 |
| Detection of FGFR Gene Mutations in the Tumor Tissue and Urine of Patients With Urothelial Carcinoma (NCT04339933) | Ho Kyung Seo | 2022-05-01 |
| The Man Van Project (NCT06357416) | Royal Marsden NHS Foundation Trust | 2022-04-13 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT05253053) | TransThera Sciences (Nanjing), Inc. | 2022-04-13 |
| Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study (NCT07657299) | Ain Shams University | 2022-04-01 |
| DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (NCT04106115) | University College, London | 2022-03-25 |
| PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05259397) | Pfizer | 2022-03-24 |
| Connecting Audio and Radio Sensing Systems to Improve Care at Home (NCT05344950) | UNC Lineberger Comprehensive Cancer Center | 2022-03-21 |
| Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC (NCT05200988) | The Netherlands Cancer Institute | 2022-03-14 |
| A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China (NCT05337189) | Creative Biosciences (Guangzhou) Co., Ltd. | 2022-03-09 |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (NCT05243550) | UroGen Pharma Ltd. | 2022-03-01 |
| Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells (NCT05108077) | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 2022-03-01 |
| Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors (NCT05235607) | Sichuan University | 2022-03-01 |
| Mapping 3D Bladder (NCT05260788) | University Health Network, Toronto | 2022-03-01 |
| Role of Microbiome in BCG Responsiveness Prediction (NCT05204199) | Cédric Poyet | 2022-02-22 |
| A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer (NCT04917809) | Memorial Sloan Kettering Cancer Center | 2022-02-17 |
| PENK Methylation Test for Detecting Bladder Cancer (NCT05220189) | Asan Medical Center | 2022-02-03 |
| Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery (NCT05392634) | N.N. Petrov National Medical Research Center of Oncology | 2022-02-02 |
| The Impact of Intrathecal Morphine Versus Continuous Epidural Analgesia on Return of Bowel Function in Patients Undergoing Laparoscopic Ileal Conduit (NCT06688643) | Xiaguang Duan | 2022-01-25 |
| A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630 (NCT05055050) | M.D. Anderson Cancer Center | 2022-01-24 |
| CARINAE for Stress Relief in Perioperative Care (NCT05184725) | Adhera Health, Inc. | 2022-01-10 |
| Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer (NCT06205277) | University of Trieste | 2022-01-01 |
| The Impact of Late Effects After Treatment for Bladder Cancer on Quality of Life (NCT05195515) | Aarhus University Hospital | 2022-01-01 |
| Phase I BLASST-3 Trial (NCT04972253) | Guru P. Sonpavde | 2021-12-23 |
| Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC (NCT04897763) | Institut Cancerologie de l'Ouest | 2021-12-15 |
| Active Surveillance vs in Office Fulguration for Low Grade Bladder Cancer Tumors (NCT05148728) | Vall Hebron Insitut Recerca | 2021-12-15 |
| Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-ID Testing Menu (IDTM) and Standard Laboratory Culture (NCT04583553) | University of Kansas Medical Center | 2021-12-15 |
| Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline) (NCT04947059) | University of Thessaly | 2021-12-14 |
| Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors (NCT05151341) | Institut de Cancérologie de Lorraine | 2021-12-13 |
| Intravesical Prostatic Protrusion Mimicking Urothelial Cell Carcinoma of the Bladder (NCT05077852) | Ankara Training and Research Hospital | 2021-12-12 |
| Bladder Cancer and ExeRcise Training During IntraVesical ThErapy (NCT04593862) | University of Alberta | 2021-12-09 |
| Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer (NCT05072600) | Peking University First Hospital | 2021-12-07 |
| Infectious Complications After Cystectomy: A Prospective Observational Study (NCT05153694) | Ludwig-Maximilians - University of Munich | 2021-12-01 |
| Gag-layer in the Urothelium of the Human Upper Urinary Tract (NCT05400291) | Aarhus University Hospital | 2021-12-01 |
| Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer. (NCT05102110) | Origin Sciences | 2021-12-01 |
| Can Four Weeks-check Cystoscopy and Urine Cytology After Primary Complete Resection of T1 Bladder Cancer Replace Repeat Biopsy? (NCT05167916) | Mansoura University | 2021-12-01 |
| Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study (NCT05180851) | Shanghai Fengxian District Central Hospital | 2021-11-30 |
| Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) (NCT05136898) | UroGen Pharma Ltd. | 2021-11-30 |
| Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib (NCT05052372) | xCures | 2021-11-21 |
| Bio Clinical Collection of Urothelial Carcinoma (NCT04970472) | University Hospital, Toulouse | 2021-11-16 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours (NCT05057013) | Cancer Research UK | 2021-11-10 |
| LaserEn: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors (NCT04979156) | University of Kansas Medical Center | 2021-11-04 |
| Validation of VI-RADS for the Detection of Detrusor Muscle Invasion (NCT05123404) | Egyptian Biomedical Research Network | 2021-11-04 |
| Outcome of Treating Bladder Cancer in Sohag University Hospital (NCT05082818) | Sohag University | 2021-10-30 |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (NCT05061537) | Pfizer | 2021-10-20 |
| A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer (NCT05016973) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2021-10-01 |
| Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer (NCT04779489) | University of Texas Southwestern Medical Center | 2021-09-06 |
| Immunological Response of Bladder Cancer Patients Under BCG (NCT04806178) | University of Campinas, Brazil | 2021-09-03 |
| Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy (NCT04487457) | University Hospital, Tours | 2021-09-03 |
| Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer (NCT05120622) | University of British Columbia | 2021-09-01 |
| Prucalopride for Postoperative Ileus in Patients Undergoing Robot-assisted Laparoscopic Radical Cystectomy (NCT05001763) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2021-09-01 |
| Establishment and Validation of an Early Diagnostic Model for Bladder Cancer Based on Serum and Urine Metabolomics (NCT04966962) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-09-01 |
| Effect and Prognosis of Immunohistochemical Biomarkers Changes in Patients With Bladder Cancer After Neoadjuvant Chemotherapy (NCT04966975) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-09-01 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| Decision Making for Urinary Diversion in Patients With Bladder Cancer (NCT05111639) | University of Colorado, Denver | 2021-08-24 |
| Hypotension Prediction Effect on AKI (NCT04994639) | Ewha Womans University Mokdong Hospital | 2021-08-24 |
| Impact of COMORBIDities After Radical Cystectomy Using a Predictive Method With Artificial Intelligence (NCT05204186) | Centre Hospitalier Universitaire, Amiens | 2021-08-12 |
| LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors (NCT04690699) | Istari Oncology, Inc. | 2021-08-01 |
| Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients (NCT04412070) | Hopital Foch | 2021-07-30 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117) | QuantumLeap Healthcare Collaborative | 2021-07-28 |
| Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors (NCT04985604) | Day One Biopharmaceuticals, Inc. | 2021-07-15 |
| Application and Clinical Effectiveness of Pelvic Reconstruction in Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder in the Male (NCT04958343) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-07-02 |
| Lateral Prostate Capsule Sparing Versus Non Nerve Sparing Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder for Bladder Cancer in the Male (NCT04958330) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-07-02 |
| A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer (NCT05508568) | Arquer Diagnostics Ltd | 2021-07-01 |
| The Effect of the COVID-19 Pandemic on Primary Bladder Cancer Presentations (NCT04900259) | Ankara Training and Research Hospital | 2021-07-01 |
| Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC (NCT05123625) | The First Affiliated Hospital with Nanjing Medical University | 2021-07-01 |
| The Personal Patient Profile Decision Support for Patients With Bladder Cancer (NCT05033067) | Icahn School of Medicine at Mount Sinai | 2021-06-10 |
| Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) (NCT04498767) | European Organisation for Research and Treatment of Cancer - EORTC | 2021-06-10 |
| Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma (NCT04701918) | Massachusetts General Hospital | 2021-06-04 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (NCT04887831) | G1 Therapeutics, Inc. | 2021-06-04 |
| Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical Outcomes (NCT04280640) | UNC Lineberger Comprehensive Cancer Center | 2021-06-01 |
| Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder (NCT04878250) | Queen Mary University of London | 2021-06-01 |
| Bladder Cancer Detection Using Convolutional Neural Networks (NCT05193656) | Zealand University Hospital | 2021-06-01 |
| Sacituzumab Govitecan Plus EV in Metastatic UC (NCT04724018) | Dana-Farber Cancer Institute | 2021-05-20 |
| Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM) (NCT05453682) | Samsung Medical Center | 2021-05-14 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| CONFIRM: Magnetic Resonance Guided Radiation Therapy (NCT04368702) | Brigham and Women's Hospital | 2021-05-01 |
| Robotic Radical Cystectomy Outcomes (NCT04900558) | University of Florence | 2021-04-29 |
| Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (NCT04700124) | Merck Sharp & Dohme LLC | 2021-04-21 |
| RESECT: Improving Quality in TURBT Surgery. (NCT05154084) | British Urology Researchers in Surgical Training | 2021-04-19 |
| Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer Patients (NCT05739968) | National Taiwan University Hospital | 2021-04-01 |
| En Bloc TURBT With Collins Loop vs Conventional TURBT (NCT05027412) | Hospital Universitario de Fuenlabrada | 2021-04-01 |
| Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (NCT03915678) | Institut Bergonié | 2021-03-31 |
| DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study) (NCT04825834) | Delfi Diagnostics Inc. | 2021-03-22 |
| Professional Bladder Cancers and the Profession of Painter (NCT05937555) | University Hospital, Brest | 2021-03-15 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT04742959) | TransThera Sciences (Nanjing), Inc. | 2021-03-14 |
| A Study of KF-0210 in Advanced Solid Tumors Patients (NCT04713891) | Keythera Pharmaceuticals (Australia) Pty Ltd | 2021-03-09 |
| Effect of Tumor Base Size in Bladder Cancer (NCT06632340) | Ankara Training and Research Hospital | 2021-03-01 |
| Use of Pedometer Following Radical Cystectomy (NCT04305730) | Benaroya Research Institute | 2021-03-01 |
| Evaluation of Naloxegol in the Prevention of POI After Cystectomy (NCT04219046) | Institut Paoli-Calmettes | 2021-03-01 |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers (NCT04464967) | NKGen Biotech, Inc. | 2021-03-01 |
| Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy (NCT04579133) | Latin American Cooperative Oncology Group | 2021-03-01 |